Nuvisan

🧬 We are Live at OCT DACH in Zurich! The NUVISAN team is excited to be at OCT DACH in Zurich, Switzerland today and tomorrow, joining global clinical trial experts for two days of insightful discussions and networking! Stop by our booth #6 to meet Jonas Kugler and Brigitte Lamontagne, and let’s explore how NUVISAN’s 40+ years of experience and comprehensive solutions can drive your drug development projects forward. Don’t miss the chance to connect with us and learn how we can support your clinical trials! #OCTDACH #ClinicalTrials #DrugDevelopment #ScienceCRO #NUVISAN

👨🏻🏫 Join NUVISAN for a talk about Streamlining TFL & Submission ready Domains with PK Submit and Phoenix WinNonlin on October 30 at the upcoming Certainty Europe 2024! Flexibility is crucial for adapting workflows to customer requests and offering customizable solutions. Join the talk of our subject matter expert for pharmacokinetics Fabian Gärtner on simultaneously generating TFLs and customized submission-ready domains using PK Submit and Phoenix WinNonlin. Discover how PK Submit streamlines processes, minimizes data entry errors, and enhances traceability, all while maintaining data integrity and regulatory compliance. Join us at the Phoenix UGM - Customer Spotlight at the upcoming Certainty Europe 2024 in Mainz, Germany on October 30, from 09:45 to 10:15. See you there! #CertaintyEurope2024 #ScienceCRO #NUVISAN

Final Call: Submission Deadline Approaching for the 2nd NUVISAN Drug Discovery Innovation Challenge! Are you ready to turn your groundbreaking idea into reality? This is your chance to collaborate with venture capitalists and scientific experts who can help propel your drug discovery projects forward! This year, we are seeking innovative solutions targeting orphan diseases and challenging drug targets. If you have a revolutionary concept and need the support to bring it to life, the 2nd NUVISAN Innovation Challenge is your perfect opportunity. 🎯 Theme: Innovative Solutions for Orphan Diseases and Challenging Drug Targets 🎁 Prizes: Winners will have the opportunity to present their ideas to venture capitalists and receive expert scientific consultation from NUVISAN. 🌐 Who Can Apply: Companies worldwide working to address these unmet needs are encouraged to participate. 📅 Submission Deadline: October 29 Don't miss out on this incredible opportunity to make a difference in the world of drug discovery! Submit your application now: https://lnkd.in/e7skKGDP

Last Chance to Register! Join us for the NUVISAN Meet & Learn event in Copenhagen, Denmark on October 29th at the BioInnovation Institute Fonden! We are thrilled about this upcoming event and can't wait to share the latest innovations in screening, medicinal chemistry, biophysics, and pharmacology with you. Hear from our experts as they present groundbreaking methods, real case studies, and key insights. Afterward, enjoy an exclusive networking session with industry peers, all while indulging in great food and drinks. 📅 Event Date: October 29th, 2024 📍 Location: BioInnovation Institute Fonden, Copenhagen ⏰ Time: 13:30 - 17:30 We look forward to seeing you at the BioInnovation Institute Fonden next week! Register at: https://lnkd.in/eSzubjZh #Networking #DrugDiscovery #MeetandLearn #NUVISAN #ScienceCRO

📢 Heike Wiese, Head of New Modalities LCMS at NUVISAN will present on Metabolomics screening kits for use in clinical trials at Pharma Conclave 2024 on October 23 from 10:00 to 10:30 CET. Join us for this insightful virtual event featuring Heike Wiese and many other industry experts. ➡ https://lnkd.in/exGRqvCm

📅 Join us for the 3rd NUVISAN Venture Capital Forum at our drug discovery hub in Berlin on November 26! The event kicks off with a powerhouse panel featuring NUVISAN thought leaders, Martin Lange, Franz von Nussbaum, Dr. George Voren, Head of Founder Strategy & Operations at Curie.Bio, and Dr. Matthew Pech, Co-founder of Big Sur, as they discuss How to Succeed in Company Creation. 💡 Following this, get ready for an exciting pitch session where 10 innovative companies including winners from 2nd NUVISAN Drug Discovery Innovation Challenge will present their groundbreaking ideas. Want to attend this exclusive event? Contact Diez Fernandez Carmen for more details. ✨Curious about the 2nd NUVISAN Drug Discovery Innovation Challenge? Want a stage to showcase your innovative idea? Find all the details here: https://lnkd.in/e7skKGDP #VentureCapital #Innovation #DrugDiscovery #Medicine #Science

NUVISAN Meet & Learn in Copenhagen is coming up soon🎉 Looking to dive deep into the latest trends, challenges, and innovative solutions in early drug discovery? Join our NUVISAN scientists for an exciting NUVISAN Meet & Learn event at the BioInnovation Institute Fonden in Copenhagen on October 29, 2024. What’s in store: 📌 A deep dive into NUVISAN's integrated degrader capabilities. 📌KRAS inhibition breakthroughs: Explore SOS1, fragment screening, and HTS. 📌Targeting the Hippo pathway in cancer: Phenotyping screening, target, and lead optimization of novel small molecule inhibitors After the presentations, enjoy networking with industry peers and thought leaders. Don’t miss out on this exclusive opportunity! Seats are limited! Secure yours today ➡ https://lnkd.in/eSzubjZh #MeetandLearn #ScienceCRO #NUVISAN #DrugDiscovery #Screening #Protacs #Oncology

📢 Visit our poster at the 36th EORTC-NCI-AACR symposium in Barcelona from October 23 to 25, 2024! Barbara Nicke, Head of Therapeutic Compound Research, will host a poster presentation on the topic: Identification and target deconvolution of novel small molecule inhibitors of oncogenic YAP1/TAZ activity. The poster highlights a large-scale cell-based phenotypic screen of 3.8 million compounds. Promising HTS hits with YAP1/TAZ-inhibitory activity were selected for further profiling and target deconvolution studies. Complementary proteomic, biophysical and biochemical methods, as well as CRISPR/Cas9 knockout screens, revealed the direct target of these inhibitors. Knowledge about the direct target of small molecule inhibitors is essential for SAR-guided compound optimization and paved the way towards optimized inhibitors with potent in vivo anti-tumor activity. 👀 Visit the poster- Barbara Nicke will be happy to explain the details and answer any questions you may have. 👉 Discovery more NUVISAN Science-> https://lnkd.in/eHdxpw4u #ENA2024 #Screening #CRISPR #ScienceCRO #NUVISAN #CancerResearch

Let Venture Capital Firms and NUVISAN Boost Your Drug Discovery Project! Are you working on an orphan disease drug discovery project or tackling challenging targets? This is your opportunity to collaborate with venture capitalists and scientific experts to propel your drug discovery initiative forward. The 2nd NUVISAN Innovation Challenge is seeking groundbreaking ideas in this space to accelerate the development of new treatments for patients in need. 🎯 Theme: Innovative Solutions for Orphan Diseases and Challenging Drug Targets 🎁 Prizes: Winners will have the opportunity to present their ideas to venture capitalists and receive expert scientific consultation from NUVISAN. 🌐 Who Can Apply: Companies worldwide working to address these unmet needs are encouraged to participate. 📅 Submission Deadline: October 29 Explore the event details here: https://lnkd.in/e7skKGDP We look forward to your application! #NUVISAN #ScienceCRO #InnovationChallenge #DrugDiscovery #OrphanDrugs #Biotech #VentureCapital

✨ Day 1 at #CPHI2024! ✨ What an incredible start to this global event! 🚀 It’s inspiring to be surrounded by industry leaders, innovators, and passionate professionals, all focused on shaping the future of #Pharma and #Healthcare. If you're attending, don't hesitate to connect – we Julian Bonss, Jean-Guy Boiteau, Isabel Dr. Zwick, Marjory GRAFFIN, Delphine MAUX, and Guillaume B. would love to discuss how we can support your project, and drive innovation together. Swing by our booth #5D139 and take a moment to join our NUVISAN guessing game for a chance to win a surprise box! The more times you join, the better your chances! https://lnkd.in/ehZATchJ #ScienceCRO #CPHI2024 #CPHIMilan #NUVISAN